Stock Ratings / Health Care / ANAB / forecast

PCRX (54) GHRS (58) TYRA (41) AAPG (57) ⌘ Pro Terminal →

AnaptysBio Inc. (ANAB) 12-Month Stock Forecast & Price Target Cone

$48.64 -3.68% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $48.23

AnaptysBio Inc. (ANAB) carries a Roarable Rating of C- (Hold) with 61/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

📊 Historical Track Record: Scores of 61/100 (C-) historically posted market-perform odds over rolling 90-day windows (+0.5% avg 90D alpha vs SPY) →

ROARABLE C- • HOLD / WATCH Cap $1.44B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $48.23 (-0.85%)🧬 Disciplined Float (+0.52% YoY Shares)⚙️ Cash Engine: 19/20 (A+) • 8.4% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 61/100 (C-) historically posted market-perform odds over rolling 90-day windows (+0.5% avg 90D alpha vs SPY • 53.9% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERHOLD / WATCH • C-

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw C- · Rk C

Each axis scored 0–20

12M PRICE TARGET CONE+1.4% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ANAB)Realized 20D OHLCV Swing Band: ±9.8%

Deterministic 5-Pillar Attribution (61/100 Composite)

🔍 WHY ANAB SCORES 61/100 (C-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Cash Engine Quality+19/20 pts (31% of score)

SEC XBRL FY 2025 (10-K): 8.4% FCF Margin ($19.6M FCF) & 52% Gross Margin

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (21% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▼ #1 Drag / Risk Factor: Whale & Options Positioning7/20 pts (-13 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-13 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C-$45.95+1.4% Next Q

Q2 (-2Q)

Grade C$46.61+4.5% Next Q

Q3 (-1Q)

Grade C$48.73-0.2% Next Q

Current

Grade C-$48.64+0.5% Hist 90D α

Trajectory: C- (53) → C- (61)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the ANAB Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 61/100 (C-) score, ANAB faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Company executives have done more routine share selling than personal cash buying lately.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Disciplined Float (+0.52% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($51.76) or 200D SMA ($50.40) invalidates the momentum regime and cuts Target Base ($49.30) toward Bear Floor ($38.45).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ANAB• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “ANAB Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 61%NO 39%Trade / Inspect Odds →

INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your ANAB Position Size: $10,000

Shares at $48.64: 205.6 sh

$1,000$10,000$25,000$50,000$100,000

12M Bear Case FloorTarget $38.45

$7,905

$-2,095 (-20.9%)

12M Consensus BaseTarget $49.30

$10,136

+$136 (+1.4%)

12M Bull Case BreakoutTarget $75.98

$15,621

+$5,621 (+56.2%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (28 Desks)

Street Historical Accuracy: 64/100

● Strong Buy / Buy: 17● Hold: 9● Sell: 2

Wall Street Firm	Stance	12M Target	1Y Accuracy	Track Grade
Morgan StanleyInstitutional Equity Desk	HOLD	$51	74%	A
Goldman SachsSector Coverage Lead	BUY	$71	69%	B
JP MorganUS Large-Cap Research	HOLD	$44	58%	C

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (ANAB Tape Review)

✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
✓Forensic Red-Light accounting & dilution traps to review on your watchlist
✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

ANAB // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -26.00%▼ DESCENDING CHANNEL

2026-10-30O $48.68H $48.97L $47.88C $48.64VOL 293.6K

RES: $68.53SUP: $43.31SMA50: $51.76SMA200: $50.40

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ANAB Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ANAB Butterfly Map → + Track ANAB →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

-7.6%/yr Implied 5Y Growth

vs. +157.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on ANAB today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ANAB. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for ANAB today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ANAB)

Health Care Rank #185 of 1016 ⚔️ PCRX vs ANAB Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ANAB vs. PCRX, GHRS, TYRA, AAPG)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, AnaptysBio Inc. (ANAB) ranks #185 by composite RQD confidence (61/100, grade C-) and #311 by equity capitalization ($1.44B). Within this direct 5-issuer industry benchmark cohort, ANAB leads on earnings valuation at N/A trailing P/E, while ANAB leads on capital efficiency and profitability with 85.0% ROIC and — gross margin. ANAB currently leads its immediate peer cohort in composite quantitative strength at 61/100 (C-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
ANAB ACTIVE AnaptysBio Inc.	C-	61/100	—	—	85.0%	-3.68%	$1.44B	Benchmark Subject
PCRX Pacira BioSciences Inc.	D+	54/100	—	79.4%	1.7%	0.00%	$1.45B	/pcrx-vs-anab →
GHRS GH Research PLC	D+	58/100	—	—	—	+3.82%	$1.47B	/ghrs-vs-anab →
TYRA Tyra Biosciences Inc.	D-	41/100	—	—	-35.0%	-1.24%	$1.48B	/tyra-vs-anab →
AAPG Ascentage Pharma Group International American Depository Shares	D+	57/100	—	—	—	-0.70%	$1.39B	/aapg-vs-anab →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001370053

In its most recent audited fiscal period (FY2025, filed 2025-12-31), AnaptysBio Inc. (ANAB) reported GAAP revenue of $234.6M (+157.0% vs. FY2024 revenue of $91.3M , and +1267.4% cumulative change since FY2023) , GAAP net income of -$13.2M, operating cash flow of $19.7M, and free cash flow of $19.6M (+114.5% YoY). On the balance sheet, ANAB closed FY2025 with $364.4M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 7/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$234.6M	-$13.2M	$19.7M	$19.6M	$364.4M	—
FY2024 (FY)	2024-12-31	$91.3M	-$145.2M	-$135.3M	-$135.7M	$483.8M	—
FY2023 (FY)	2023-12-31	$17.2M	-$163.6M	-$120.8M	-$120.8M	—	—

3. ANAB Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ANAB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, AnaptysBio Inc. (NASDAQ: ANAB) is rated C- (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 61/100 at a spot price of $48.64 (-3.68% 1D, market cap $1.44B). Pillar breakdown: Fundamental Cash Engine 19/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 10/20. Across 1016 tracked Health Care issuers, ANAB ranks #185 in composite RQD confidence.

How does ANAB compare to PCRX and GHRS in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ANAB carries a Roarable C- (61/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of 85.0%. By comparison, PCRX (Pacira BioSciences Inc.) holds a D+ grade (54/100 RQD, P/E N/A, ROIC 1.7%, cap $1.45B) and GHRS (GH Research PLC) posts a D+ grade (58/100 RQD, P/E N/A, ROIC —, cap $1.47B). Among the 5-stock peer group, ANAB leads on earnings multiple (N/A) while ANAB leads on capital efficiency (85.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for ANAB?

Per ANAB's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001370053), AnaptysBio Inc. generated $234.6M in revenue (+157.0% YoY), -$13.2M in net income, and $19.6M in free cash flow against $364.4M in total assets and $0 in total debt. Key quantitative strengths: Strong cash generator (steady margins)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is ANAB trading relative to its 50-day, 200-day, and 52-week technical levels?

ANAB last traded at $48.64 (-3.68% on volume of 414,400 shares), positioning the stock -6.03% below its 50-day simple moving average ($51.76) and -3.49% below its 200-day simple moving average ($50.40). Across its 52-week range of $20.18 to $72.36, ANAB sits at the 54.5% percentile with a 14-day RSI of 46.7 (NEUTRAL RANGE) and an implied next-earnings move of ±9.8% ($43.87 to $53.41).

ANAB Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is ANAB's 12-month stock price target?

AnaptysBio Inc. (ANAB) carries a 12-month consensus base price target of $49.3 (+1.4% from $48.64), with a bull-case target of $75.98 and a bear-case floor of $38.45.

Is ANAB stock a Buy, Hold, or Sell right now?

Roarable's 5-Pillar RQD Quant Engine rates ANAB C- (Hold — HOLD) with an RQD Confidence score of 61/100.

Direct Sub-Reports: ANAB RQD Cockpit ANAB 12M Forecast ANAB Earnings & Move ANAB Dividends & DRIP ANAB Insiders & 13F ANAB Whale Options ANAB Profit Sankey ANAB News & Why